The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease

Brugts, Jasper J.; Arima, Hisatomi; Remme, W. J.; Bertrand, Michel E.; Ferrari, Roberto; Fox, Kim; DiNicolantonio, James J.; MacMahon, Stephen; Chalmers, John; Zijlstra, Felix; Çalışkan, Kadir; Simoons, Maarten L.; Mourad, Jean‐Jacques; Boersma, Eric; Akkerhuis, K. Martijn

doi:10.1016/j.ijcard.2014.07.108

Cited by 62 publications

(63 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast with findings of Brugts et al. that found the risk of developing of cough increases in patients who were above 65 years old. This study analyzed individual data from three large randomized clinical trials of patients who had cough due to ACE inhibitors.…”

Section: Discussioncontrasting

confidence: 99%

“…However, in a study using pediatric hypertension patient-level data from eight randomized controlled trials conducted by Smith et al [7], it was found that there was no significant difference of cough incidence in children using ACE inhibitors compared to ARBs users [(17/524 (3.2%) and 4/224 (1.8%), respectively; P-value = 0.34)]. Moreover, most studies have observed that women have a higher incidence of cough than men in patients using ACE inhibitors [8][9][10][11][12]. Only a few studies observed that the incidence of ACE inhibitors-angioedema is higher in female patients than in male as well as in elderly patients [6,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of age and sex on the reporting of cough and angioedema with renin–angiotensin system inhibitors: a case/noncase study in VigiBase

Alharbi

Kholod

Souverein

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The purpose of this study was to assess the impact of age and sex on the reporting of cough and angioedema related to renin-angiotensin system (RAS) inhibitors. A case/noncase study was performed in VigiBase. Two case groups were identified, reports of cough and reports of angioedema, and noncases were all reports of all other adverse events. Logistic regression analysis was used to assess the association between reporting of cough and angioedema with each class of RAS inhibitors stratified by age/sex and to control for confounding. The reporting of cough with angiotensin-converting enzyme (ACE) inhibitors was significantly higher in women than in men [adjusted reporting odds ratio (ROR): 44.0, 95% CI (43.2-44.8) for women vs. 29.2, 95% CI (28.5-29.9) for men]. There was no difference in reporting of cough linked to angiotensin receptor blockers (ARBs) and aliskiren between men and women. In contrast, the reporting of angioedema with ACE inhibitors and ARBs was significantly higher in men than in women, but for aliskiren, women had a significantly higher ROR than men [adjusted ROR: 5.20,) for women vs. 3.04, 95% CI (2.30-4.02) for men]. The reporting of cough with ACE inhibitors was increased with age until reaching a plateau at middle adulthood (40-59 years) and the reporting of angioedema with ACE inhibitors was increased with age until elderly (60-79 years). Age had only a slight effect on the reporting of cough and angioedema with ARBs and aliskiren. Both age and sex have substantial effects on the reporting of cough and angioedema with RAS inhibitors and in particular ACE inhibitors. Further study is needed to determine whether these differences mainly express different adverse drug reaction risks in subgroups or also can be explained by factors influencing reporting.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The impact of age and sex on the reporting of cough and angioedema with renin–angiotensin system inhibitors: a case/noncase study in VigiBase

Alharbi

Kholod

Souverein

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Fourthly, late adverse drug reaction to the ACEIs can occur up to thirteen years of medicine use. Frequent side effects associated with the use of ACEIs family of anti-hypertensive medicines are intractable non-productive cough and the conspicuous labial-facial angio-edema or Quincke’s edema [3, 7]. When any of these occur, the drug and related medicines are immediately stopped and black listed for the patient.…”

Section: Discussionmentioning

confidence: 99%

“…In this case, adding twice daily vitamin B (that can be forgone) erroneously induced this elderly woman to quadruple her anti-hypertensive medicine with the risk of hypotension and falls [5, 6, 11]. Patients on ACEIs, especially the elderly, should monitored regularly for late onset adverse drug reactions [7]. …”

Section: Discussionmentioning

confidence: 99%

A case management of hypertension in the elderlyin sub-Sahara Africa: lessons from Granny

2017

View full text Add to dashboard Cite

Management of chronic disease conditions in the elderly is challenging. They usually have many co-morbidities requiring multiple drug regimens, and memory or cognitive problems that can interfere with management. Also, they sometimes have a degree of social problems as they might often live alone, and thereby cater for their daily activities with minimal assistance. Multiple drug use combined with their fragile health predispose them to adverse drug reactions, drug-drug interactions, and direct drug toxicity from overdosing. We report and discuss the lessons learnt from the case of an elderly woman in an urban setting in sub-Saharan Africa who presented with problems of drug dosing, adverse drug effect, and drug-drug interaction that might prove useful in the future management of hypertension with angiotensin converting enzyme inhibitors.

show abstract

“…However, these synthetic drugs exert several side effects, including cough, skin rashes, hypotension, hyperkalemia, headache, dizziness, and renal impairment. [4,5] Food-derived ACE inhibitors are safer than synthetic compounds. [6] To date, many ACE-inhibitory peptides have been isolated from food proteins, such as egg yolk protein, Agaricus bisporus, whey protein, and gluten.…”

Section: Introductionmentioning

confidence: 99%

Purification and identification of angiotensin I-converting enzyme inhibitory peptides from fermented walnut residues

Zheng

Li²,

Ding

2017

International Journal of Food Properties

View full text Add to dashboard Cite

Defatted walnut residues (DWR) were hydrolysed using Bacillus subtilis to produce angiotensin-I-converting enzyme (ACE) inhibitory peptides. Fermented walnut residue extract (FWRE) was fractionated using ultrafiltration methods to identify the ACE-inhibitory peptides. The fraction with a molecular weight of <1 kDa (WPs-I) presented the greatest ACE-inhibitory activity. Reverse-phase high-performance liquid chromatography was used to separate WPs-I from the most active fractions, and the amino acid sequence of WPs-I was confirmed as VQTL (459.351 Da) and LGYEN (594.276 Da) by UPLC-ESI-MS/MS. ARTICLE HISTORY

show abstract

The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease

Cited by 62 publications

References 23 publications

The impact of age and sex on the reporting of cough and angioedema with renin–angiotensin system inhibitors: a case/noncase study in VigiBase

The impact of age and sex on the reporting of cough and angioedema with renin–angiotensin system inhibitors: a case/noncase study in VigiBase

A case management of hypertension in the elderlyin sub-Sahara Africa: lessons from Granny

Purification and identification of angiotensin I-converting enzyme inhibitory peptides from fermented walnut residues

Contact Info

Product

Resources

About